江苏汇典律师事务所 关于江苏森萱医药股份有限公司 2024 年第一次临时股东大会 之 法律意见书 江苏 江苏省镇江市檀山路 汇典律师楼 邮编:212001 电话:0511-83815006 传真:0511-85600148 网址: http://www.hdlawyer.com.cn/ 二〇二四年五月 江苏汇典律师事务所 按照律师行业公认的业务标准、道德规范和勤勉尽责精神,本所律师对本 次股东大会的相关资料和事实行了核查和验证,现发表法律意见如下: 关于江苏森萱医药股份有限公司 2024 年第一次临时股东大会之 法律意见书 汇典意字[2024]第【308】号 致:江苏森萱医药股份有限公司 江苏汇典律师事务所(以下简称"本所")接受江苏森萱医药股份有限公 司(以下简称"森萱医药"或"公司"）委托,指派本所宋家明律师和梁玮律 师出席森萱医药 2024 年第一次临时股东大会(以下简称"本次股东大会"), 对本次股东大会的合法性进行见证,并出具本法律意见书。 本法律意见根据《中华人民共和国公司法》(以下简称"《公司法》") 等法律、法规和规范性文件及《江苏森萱医药股份有限公司章程》(以下简称 "《公司章程》")出具。 ...

江苏森萱医药股份有限公司 2.会议召开地点：：南通市崇川区观音山街道青年中路 198 号国城生活广场 A 座 21 楼会议室 3.会议召开方式：现场投票和网络投票相结合 4.会议召集人：董事会 证券代码：830946 证券简称：森萱医药 公告编号：2024-044 江苏森萱医药股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 5 月 29 日 5.会议主持人：吴玉祥 6.召开情况合法、合规、合章程性说明： 本次股东大会的召开符合《公司法》等有关法律、法规及《公司章程》的规 定。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 4 人，持有表决权的股份总数 309,111,944 股，占公司有表决权股份总数的 72.405403%。 其中通过网络投票参与本次股东大会的股东共 1 人，持有表决权的股份总数 212,604 股，占公司有表决权股份总数的 0.0498%。 （三 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-046 江苏森萱医药股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏森萱医药股份有限公司 2023 年年度权益分派方案已获 2024 年 5 月 13 日召开的股东大会审议通过，本次实施分配方案距离股东大会审议通过的时间未 超过两个月。 现将权益分派事宜公告如下： 本次权益分派基准日合并报表归属于母公司的未分配利润为 447,972,391.44 元，母公司未分配利润为 72,761,452.80 元。本次权益分派共计派发现金红利 68,306,934.40 元。 一、权益分派方案 1、本公司 2023 年年度权益分派方案为： 以公司现有总股本 426,918,340 股为基数，向全体股东每 10 股派 1.6 元人民 币现金。 2、扣税说明 （1）个人股东、投资基金适用股息红利差别化个人所得税政策, 个人股东、 投资基金持股 1 个月（含 1 个月）以内，每 1 ...

Group 1: Company Performance - The company's revenue and net profit experienced a decline in 2023 due to decreased demand for certain products and intensified competition, leading to a significant drop in sales prices [4] - The company plans to implement a "dual circulation" strategy to maintain existing markets and explore new ones, while enhancing its competitive edge through cost management and new product development [4] Group 2: Fundraising and Investment Projects - The company has changed its fundraising project from "20 tons/year of Ritonavir and 30 tons/year of Dipyridamole raw material expansion project" to "annual production of 40 tons of Ritonavir and 60 tons of Buflomedil raw material construction project," with an investment of 6.0448 million yuan so far [4] - The company is focused on efficient investment strategies, emphasizing safety and quality in future investments while continuing to operate existing projects [8] Group 3: ESG and Corporate Governance - The company is preparing to disclose an ESG report, focusing on organizational structure, historical data collection, and cultural transmission [4] - The company aims to enhance its corporate governance and maintain good communication with capital market participants to improve its market value [6] Group 4: Market and Product Development - The new drug Letermovir has not yet generated sales, as discussions with downstream formulation manufacturers are ongoing [5] - The company is committed to its development strategy of refining raw materials, specializing in intermediates, expanding new materials, and positioning itself in generic and innovative drugs [4][8] Group 5: Operational Challenges - The subsidiary in Ningxia has not resumed operations, and the company is actively coordinating the resumption process [7] - The company holds 500 to 600 million yuan in cash and remains optimistic about the pharmaceutical industry's future, focusing on strategic investments [8]

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-036 江苏森萱医药股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 2020 年 7 月 13 日，江苏森萱医药股份有限公司发行普通股 60,000,000 股， 发行方式为询价发行，发行价格为 5.40 元/股，募集资金总额为 324,000,000 元， 实际募集资金净额为 300,084,000 元，到账时间为 2020 年 7 月 16 日，为规范募 集资金管理，保护投资者合法权益，根据相关规定，公司对募集资金进行专户 存储管理，并与开源证券股份有限公司（以下简称"开源证券"）、江苏张家 港农村商业银行股份有限公司南通分行签订了《募集资金专户三方监管协议》； 截止 2023 年 12 月 31 日，募集资金余额 10,319.59 万元。 二、 本次增设募集资金专户并签署三方监管协议的情况 2023年12月6日，公司召开第四届董事会第一次会议、第四届监事会第一次 会议，分 ...

Group 1: Company Performance - The company's revenue and net profit experienced a decline in 2023 due to decreased demand for certain products and intensified competition, leading to a significant drop in sales prices [4] - The company plans to implement a "dual circulation" strategy to maintain existing markets and explore new ones, while enhancing its competitive edge through cost management and new product development [4] Group 2: Fundraising and Investment Projects - The company has changed its fundraising project from "20 tons/year of Ritonavir and 30 tons/year of Dipyridamole raw material expansion project" to "annual production of 40 tons of Ritonavir and 60 tons of Buflomedil raw materials," with an investment of 6.0448 million yuan so far [4] - The company is focused on efficient investment strategies, emphasizing safety and quality in future investments while managing existing projects [8] Group 3: ESG and Corporate Governance - The company is preparing to disclose an ESG report, focusing on organizational structure, historical data collection, and cultural transmission [4] - The company aims to enhance its corporate governance and maintain good communication with capital market participants to improve its market value [6] Group 4: Market and Product Development - The new drug Letermovir has not yet generated sales, as discussions with downstream manufacturers are ongoing [5] - The company is committed to its development strategy of refining raw materials, specializing in intermediates, expanding new materials, and positioning itself in generic and innovative drugs [4][8] Group 5: Operational Challenges - The subsidiary in Ningxia has not resumed operations, and the company is actively coordinating the reopening process [7] - The company holds 500 to 600 million yuan in cash and is cautious about investments, focusing on the pharmaceutical industry's growth potential [8]

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-032 江苏森萱医药股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼 会议室 3.会议召开方式：以现场加通讯方式召开 4.发出董事会会议通知的时间和方式：2024 年 4 月 19 日以日以书面、邮件 等方式发出 5.会议主持人：吴玉祥 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 28 日 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事袁拥军、钱卫峰、沈小燕、任勇因出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2024 年第一季度报告>的议案》 1.议案 ...

开源证券股份有限公司 关于江苏森萱医药股份有限公司持续督导之 保荐工作总结报告 开源证券股份有限公司(以下简称"开源证券"、"保荐人")作为江苏 森萱医药股份有限公司(以下简称"森萱医药"、"公司")持续督导的保荐 人,持续督导期间为 2020年 7 月 27 日至 2023 年 12 月 31 日。森萱医药于 2024 年 4 月 18 日披露《2023年年度报告》,根据《北京证券交易所证券发行上 市保荐业务管理细则》《北京证券交易所股票上市规则(试行)》等相关法律法 规文件要求,开源证券现出具保荐工作总结报告书,具体内容如下: 一、保荐人及保荐代表人承诺 1、保荐工作总结报告书和证明文件及其相关资料的内容不存在虚假记载、 误导性陈述或重大遗漏,保荐人及保荐代表人对其真实性、准确性、完整性承 担法律责任。 2、本保荐人及本人自愿接受中国证监会对保荐工作总结报告书相关事项进 行的任何质询和调查。 3、本保荐人及本人自愿接受中国证监会及北京证券交易所(以下简称"北 交所")按照《北京证券交易所证券发行上市保荐业务管理细则》《北京证券交 易所上市公司持续监管办法(试行)》等有关规定采取的监管措施。 保荐人名称 开 ...

Financial Performance - Net profit attributable to shareholders decreased by 23.21% to CNY 34,861,755.22 for Q1 2024, down from CNY 45,399,312.04 in Q1 2023[12] - Operating revenue for Q1 2024 was CNY 137,674,996.19, representing a decline of 21.40% compared to CNY 175,152,565.78 in the same period last year[12] - The weighted average return on net assets based on net profit attributable to shareholders was 3.02% for Q1 2024, down from 4.09% in Q1 2023[12] - Total operating revenue for Q1 2024 was CNY 137,674,996.19, a decrease from CNY 175,152,565.78 in Q1 2023, representing a decline of approximately 21.5%[40] - Total operating costs for Q1 2024 were CNY 97,935,912.87, down from CNY 121,282,349.06 in Q1 2023, indicating a reduction of about 19.2%[40] - The net profit for Q1 2024 was CNY 1,260,452.45, an increase from CNY 912,375.25 in Q1 2023, representing a growth of approximately 38%[43] - The total profit for Q1 2024 was CNY 1,735,801.74, an increase from CNY 1,256,211.59 in Q1 2023, representing a growth of approximately 38%[43] - The basic earnings per share for Q1 2024 was CNY 0.0817, down from CNY 0.1063 in Q1 2023, reflecting a decrease of about 23%[42] Cash Flow - The net cash flow from operating activities decreased by 19.86% to CNY 19,833,649.82 in Q1 2024, down from CNY 24,748,327.96 in Q1 2023[12] - Cash received from operating activities increased by 1,684,260.57 yuan, up 168.24% compared to the previous period, mainly due to an increase in interest income[15] - Cash paid for various taxes decreased by 10,316,710.10 yuan, down 46.90%, primarily due to the expiration of tax deferral policies for small and micro enterprises[15] - Cash paid for other operating activities decreased by 3,768,800 yuan, down 42.07%, mainly due to a reduction in transportation costs[15] - The cash inflow from operating activities in Q1 2024 was CNY 115,291,036.73, compared to CNY 140,961,929.11 in Q1 2023, a decrease of approximately 18%[45] - The cash outflow from operating activities in Q1 2024 was CNY 95,457,386.91, down from CNY 116,213,601.15 in Q1 2023, indicating a reduction of about 18%[45] - The total cash outflow from operating activities in Q1 2024 was 1,855,899.69, down from 3,510,686.41 in Q1 2023, reflecting a decrease of approximately 47.3%[48] - The cash flow from operating activities netted a total of 1,435,065.57 in Q1 2024, indicating a positive trend in operational cash generation[47] Assets and Liabilities - Total assets increased by 1.75% to CNY 1,350,576,245.07 as of March 31, 2024, compared to CNY 1,327,313,296.09 at the end of 2023[12] - The company's debt-to-asset ratio decreased to 7.69% in Q1 2024 from 8.87% at the end of 2023[12] - Total liabilities decreased to CNY 103,905,317.35 as of March 31, 2024, from CNY 117,735,441.12 at the end of 2023, a reduction of approximately 11.8%[36] - The company's total equity increased to CNY 1,246,670,927.72 as of March 31, 2024, compared to CNY 1,209,577,854.97 at the end of 2023, representing an increase of about 3.1%[36] - The total liabilities to equity ratio improved to approximately 8.33 as of March 31, 2024, down from 9.73 at the end of 2023, indicating a strengthening of the company's financial position[36] Investments and Expenses - Construction in progress increased by 138.00% to CNY 23,454,152.42, primarily due to investments in new production projects[13] - Research and development expenses increased to CNY 7,116,442.26 in Q1 2024, compared to CNY 5,774,630.02 in Q1 2023, reflecting a growth of approximately 23.2%[40] - The company reported a fair value gain of CNY 594,616.44 in Q1 2024, compared to CNY 694,750.68 in Q1 2023, reflecting a decrease of about 14%[43] - The company experienced a credit impairment loss of CNY -455.00 in Q1 2024, compared to CNY 410.00 in Q1 2023, indicating a worsening in credit quality[43] Shareholder Information - The total number of ordinary shares at the end of the period was 426,918,340, with 99.9517% being unrestricted shares[20] - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 308,724,340 shares, accounting for 72.3146% of the total shares[22] - The company did not have any pledged or judicially frozen shares during the reporting period[23] Other Financial Metrics - The company reported a total of CNY 24,461,685.30 in assets under pledge or mortgage, accounting for 1.81% of total assets[30] - The company executed daily related transactions with a total expected amount of CNY 15 million for raw materials, but only CNY 25,530.98 was incurred in the reporting period[29] - The company recorded CNY 1,594,876.10 in sales of products and services against an expected amount of CNY 40 million for the year[29] - The company's cash and cash equivalents increased to CNY 513,461,081.25 as of March 31, 2024, compared to CNY 505,949,141.18 at the end of 2023[34] - The company’s accounts receivable rose to CNY 42,131,543.54 from CNY 34,237,921.14, indicating a growth in credit sales[34] - The company’s fixed assets decreased to CNY 341,639,869.66 from CNY 352,114,874.54, reflecting asset depreciation[34] - The company’s inventory stood at CNY 146,378,353.94, slightly up from CNY 145,993,690.74, indicating stable stock levels[34]

江苏森萱医药股份有限公司 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 28 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼会议 室 3.会议召开方式：以现场加通讯方式召开 证券代码：830946 证券简称：森萱医药 公告编号：2024-033 江苏森萱医药股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 具体内容详见公司于同日在北京证券交易所信息披露平台（www.bse.cn）披 露的《2023 年第一季度报告》（公告编号：2024-031）。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 4.发出监事会会议通知的时间和方式：2024 年 4 月 19 日以书面、邮件等方式发 出 5.会议主持人：秦建 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 会议应出席监事 3 人，出 ...